SDZ MRL 953

monosaccharide lipid A analog which has improved activity in experimental sepsis

Also Known As:

2-deoxy-3,4-bis-O-(3-hydroxytetradecanoyl)-2-(3-hydroxytetradecanoylamido)-1-O-phosphono-alpha-D-glucopyranose; SDZ MRL-953; alpha-D-Glucopyranose, 2-deoxy-2-((3-hydroxy-1-oxotetradecyl)amino)-, 1-(dihydrogen phosphate) 3,4-bis(3-hydroxytetradecanoate), (2(R),3(R),4(R))-

Networked: 5 relevant articles (4 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Sepsis (Septicemia) 03/01/1991 - "SDZ MRL 953, a novel immunostimulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis." 03/01/1991 - "Effect of SDZ MRL 953 on the survival of mice with advanced sepsis that cannot be cured by antibiotics alone." 08/15/1997 - "Induction of tolerance to the endotoxin-mediated cascade of proinflammatory cytokines by pretreatment with SDZ MRL 953 in patients at risk may help to prevent complications of gram-negative sepsis." 03/01/1991 - "SDZ MRL 953, a novel monosaccharidic lipid A analog as a prototype immunostimulant, and cefotaxime or gentamicin were administered to normal or myelosuppressed mice in a state of advanced sepsis caused by Escherichia coli or Staphylococcus aureus. "
2.	Infections 03/01/1991 - "The results presented here suggest that SDZ MRL 953 may be useful in a clinical setting for enhancing resistance to infections, particularly in patients undergoing myelosuppressive chemotherapy or irradiation, and for the prophylaxis of endotoxin shock." 03/01/1991 - "In conclusion, the results of the present study indicate that SDZ MRL 953 is a potential candidate for use in a clinical setting as an adjunct to antimicrobial therapy for infections that cannot be treated successfully with appropriate antibiotics alone."
3.	Septic Shock (Toxic Shock Syndrome) 03/01/1991 - "The results presented here suggest that SDZ MRL 953 may be useful in a clinical setting for enhancing resistance to infections, particularly in patients undergoing myelosuppressive chemotherapy or irradiation, and for the prophylaxis of endotoxin shock." 03/01/1994 - "Protective effects of SDZ MRL 953, a monosaccharidic lipid A analog with a reduced toxicity, were investigated in models of experimental septic shock caused by injections of LPS, and inoculations of heat-killed or live bacteria. "
4.	Shock 08/15/1997 - "The synthetic lipid A analog SDZ MRL 953 has been shown to be protective against endotoxic shock and bacterial infection in preclinical in vivo models. "
5.	Bacterial Infections (Bacterial Infection) 08/15/1997 - "The synthetic lipid A analog SDZ MRL 953 has been shown to be protective against endotoxic shock and bacterial infection in preclinical in vivo models. "

Related Drugs and Biologics

1.	Lipid A
2.	Endotoxins
3.	Anti-Bacterial Agents (Antibiotics)
4.	Cytokines
5.	Gentamicins (Gentamicin)
6.	Cefotaxime (Kendrick)
7.	Immunologic Adjuvants (Immunologic Adjuvant)

Related Therapies and Procedures

1.	Therapeutics
2.	Injections
3.	Drug Therapy (Chemotherapy)